HC Wainwright Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR)

HC Wainwright assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $65.00 price objective on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ Q1 2024 earnings at ($1.43) EPS, Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.41) EPS, Q4 2024 earnings at ($1.56) EPS, FY2024 earnings at ($5.75) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.28) EPS and FY2028 earnings at ($6.25) EPS.

Several other research analysts have also recently issued reports on JSPR. Oppenheimer reaffirmed an outperform rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Royal Bank of Canada assumed coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an outperform rating and a $70.00 price target for the company. TD Cowen started coverage on Jasper Therapeutics in a research report on Monday, March 18th. They issued an outperform rating for the company. Finally, Evercore ISI assumed coverage on Jasper Therapeutics in a research report on Wednesday, April 3rd. They set an outperform rating and a $65.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $64.29.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $21.42 on Monday. The company has a market cap of $322.59 million, a price-to-earnings ratio of -3.45 and a beta of 2.25. The stock’s 50-day moving average is $25.52 and its two-hundred day moving average is $15.12. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.15. Equities research analysts anticipate that Jasper Therapeutics will post -5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds have recently bought and sold shares of JSPR. Opaleye Management Inc. purchased a new position in shares of Jasper Therapeutics during the fourth quarter valued at approximately $3,144,000. Kingdon Capital Management L.L.C. raised its stake in Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after purchasing an additional 500,000 shares during the period. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics in the fourth quarter valued at $197,000. Cowen AND Company LLC purchased a new stake in Jasper Therapeutics during the third quarter valued at about $140,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Jasper Therapeutics in the 1st quarter valued at about $2,343,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.